Clinical Trial Update: JAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa Trial [Phase 2]

View source ↗

Summary

An open-label, single-arm Phase IIa trial evaluating JAK inhibitors for immune checkpoint inhibitor-related dermatitis in patients with solid malignant tumors; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatitis

Drugs mentioned

• JAK inhibitors (Janus kinase inhibitors)

Snippet

Sponsor: Shixiu Wu | Conditions: Immune Checkpoint Inhibitors (ICI)-Related Dermatitis | Phase 2 | Status: RECRUITING